Bartlett & Co’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $19.3M | Buy |
124,971
+2,049
| +2% | +$299K | 0.31% | 67 |
|
|
2023
Q3 | $18.3M | Sell |
122,922
-1,710
| -1% | -$251K | 0.33% | 68 |
|
|
2023
Q2 | $16.8M | Buy |
124,632
+11,950
| +11% | +$1.75M | 0.29% | 73 |
|
|
2023
Q1 | $18M | Sell |
112,682
-1,458
| -1% | -$223K | 0.35% | 69 |
|
|
2022
Q4 | $18.4M | Sell |
114,140
-72
| -0.1% | -$11K | 0.37% | 69 |
|
|
2022
Q3 | $15.3M | Buy |
114,212
+1,852
| +2% | +$266K | 0.33% | 70 |
|
|
2022
Q2 | $17.2M | Sell |
112,360
-830
| -0.7% | -$127K | 0.35% | 68 |
|
|
2022
Q1 | $18.3M | Buy |
113,190
+1,173
| +1% | +$170K | 0.32% | 74 |
|
|
2021
Q4 | $15.2M | Sell |
112,017
-3,785
| -3% | -$447K | 0.26% | 79 |
|
|
2021
Q3 | $12.5M | Sell |
115,802
-270
| -0.2% | -$30.9K | 0.24% | 83 |
|
|
2021
Q2 | $13.1M | Sell |
116,072
-1,874
| -2% | -$211K | 0.25% | 80 |
|
|
2021
Q1 | $12.8M | Sell |
117,946
-3,175
| -3% | -$340K | 0.26% | 80 |
|
|
2020
Q4 | $13M | Sell |
121,121
-1,111
| -0.9% | -$107K | 0.28% | 74 |
|
|
2020
Q3 | $10.7M | Sell |
122,232
-1,455
| -1% | -$137K | 0.25% | 79 |
|
|
2020
Q2 | $12.1M | Sell |
123,687
-1,525
| -1% | -$134K | 0.32% | 74 |
|
|
2020
Q1 | $9.54M | Buy |
+125,212
| New | +$10.7M | 0.29% | 80 |
|
|
2019
Q3 | $9.76M | Buy |
128,900
+18,767
| +17% | +$1.29M | 0.26% | 93 |
|
|
2019
Q2 | $8.01M | Sell |
110,133
-2,300
| -2% | -$181K | 0.3% | 72 |
|
|
2019
Q1 | $9.06M | Sell |
112,433
-4,410
| -4% | -$361K | 0.35% | 68 |
|
|
2018
Q4 | $10.8M | Sell |
116,843
-4,010
| -3% | -$353K | 0.46% | 61 |
|
|
2018
Q3 | $11.4M | Sell |
120,853
-1,561
| -1% | -$148K | 0.43% | 61 |
|
|
2018
Q2 | $11.3M | Buy |
122,414
+175
| +0.1% | +$17.1K | 0.46% | 62 |
|
|
2018
Q1 | $11.6M | Sell |
122,239
-11,138
| -8% | -$1.22M | 0.48% | 64 |
|
|
2017
Q4 | $12.9M | Sell |
133,377
-2,065
| -2% | -$195K | 0.51% | 60 |
|
|
2017
Q3 | $12M | Sell |
135,442
-610
| -0.4% | -$46.4K | 0.5% | 61 |
|
|
2017
Q2 | $9.87M | Sell |
136,052
-3,450
| -2% | -$232K | 0.44% | 68 |
|
|
2017
Q1 | $9.09M | Sell |
139,502
-1,410
| -1% | -$88.6K | 0.41% | 67 |
|
|
2016
Q4 | $8.82M | Sell |
140,912
-931
| -0.7% | -$56.8K | 0.42% | 67 |
|
|
2016
Q3 | $8.95M | Sell |
141,843
-801
| -0.6% | -$51.9K | 0.43% | 64 |
|
|
2016
Q2 | $8.83M | Sell |
142,644
-13,407
| -9% | -$817K | 0.44% | 63 |
|
|
2016
Q1 | $8.91M | Sell |
156,051
-8,051
| -5% | -$449K | 0.45% | 64 |
|
|
2015
Q4 | $9.72M | Sell |
164,102
-110,283
| -40% | -$6.35M | 0.5% | 57 |
|
|
2015
Q3 | $14.9M | Sell |
274,385
-6,144
| -2% | -$400K | 0.82% | 44 |
|
|
2015
Q2 | $18.8M | Sell |
280,529
-34,737
| -11% | -$2.27M | 0.95% | 40 |
|
|
2015
Q1 | $18.5M | Sell |
315,266
-249,900
| -44% | -$15.1M | 0.92% | 41 |
|
|
2014
Q4 | $37M | Sell |
565,166
-12,252
| -2% | -$772K | 1.78% | 19 |
|
|
2014
Q3 | $33.4M | Sell |
577,418
-11,614
| -2% | -$645K | 1.61% | 22 |
|
|
2014
Q2 | $33.2M | Sell |
589,032
-8,032
| -1% | -$421K | 1.6% | 23 |
|
|
2014
Q1 | $30.7M | Sell |
597,064
-2,449
| -0.4% | -$124K | 1.53% | 23 |
|
|
2013
Q4 | $31.7M | Sell |
599,513
-5,958
| -1% | -$293K | 1.58% | 23 |
|
|
2013
Q3 | $27.1M | Sell |
605,471
-5,606
| -0.9% | -$249K | 1.47% | 26 |
|
|
2013
Q2 | $25.3M | Buy |
+611,077
| New | +$26.7M | 1.39% | 27 |
|
Other funds holding ABBV
Bartlett & Co's ABBV Position: Q4 2023 in Review
Bartlett & Co increased its AbbVie (ABBV) stake by 1.7% in Q4 2023, buying an estimated $299K and bringing the position to 124,971 shares worth $19.3M. The position accounts for 0.31% of the portfolio, ranked #67.
Bartlett & Co first reported a position in ABBV in Q2 2013 and has held it in 42 quarters since. The position peaked at $37M in Q4 2014. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.
- Bartlett & Co held 124,971 shares of AbbVie worth $19.3M as of Q4 2023.
- Bartlett & Co bought 2,049 AbbVie shares in Q4 2023, an estimated $299K.
- AbbVie made up 0.31% of Bartlett & Co's portfolio in Q4 2023, its #67 holding.
- Bartlett & Co first reported a position in AbbVie in Q2 2013 and has held it in 42 quarters since.
- Bartlett & Co's AbbVie position peaked at $37M in Q4 2014.
- 3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.
Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.